Latest news with #RocheHoldingAG
Bloomberg
2 days ago
- Health
- Bloomberg
Roche to Test Whether New Drug Can Prevent Alzheimer's Disease
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmaking. The new late-stage study will focus on people who are at risk of cognitive decline, Roche said in a statement late Sunday. The goal would be to slow down the emergence of symptoms, or prevent them entirely.
Business Insider
3 days ago
- Business
- Business Insider
DZ BANK AG Reaffirms Their Buy Rating on Roche Holding AG (RHHVF)
DZ BANK AG analyst Elmar Kraus maintained a Buy rating on Roche Holding AG on July 25. The company's shares closed last Friday at $330.52. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kraus covers the Healthcare sector, focusing on stocks such as Novartis AG, AstraZeneca, and Koninklijke Philips N.V.. According to TipRanks, Kraus has an average return of 8.1% and a 68.85% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $353.24 average price target, which is a 6.87% upside from current levels. In a report released on July 25, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a CHF296.00 price target. Based on Roche Holding AG's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $30.65 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $28.94 billion and had a net profit of $4.36 billion
Bloomberg
4 days ago
- Health
- Bloomberg
Sarepta-Roche Gene Therapy Fails to Get EU Regulator Approval
Roche Holding AG's gene therapy Elevidys failed to get the backing of European regulators. The European Medicines Agency's drug advisory committee recommended against Elevidys for children with Duchenne muscular dystrophy, the agency said Friday. The medicine had been intended for children aged 3 to 7 years who are able to walk.
Globe and Mail
6 days ago
- Business
- Globe and Mail
Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG, with a price target of CHF235.00. The company's shares closed yesterday at $321.46. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 51.43% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and AstraZeneca. In addition to Deutsche Bank , Roche Holding AG also received a Sell from J.P. Morgan's Richard Vosser in a report issued yesterday. However, on July 17, Berenberg Bank maintained a Hold rating on Roche Holding AG (Other OTC: RHHVF). The company has a one-year high of $354.19 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 11.61K.
Bloomberg
21-07-2025
- Health
- Bloomberg
Roche Suffers Setback as Lung Drug Gets Mixed Result in Trial
Roche Holding AG 's experimental drug for a deadly lung condition got mixed results in trials, a setback as the company seeks to accelerate the development of new treatments. The late-stage trials for astegolimab — the medicine being developed to treat chronic obstructive pulmonary disease, or COPD — offered contrasting results, according to a statement on Monday.
